Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel combined single dose anti-hepatitis C therapy: a pilot study.

Scientific reports - 25 Feb 2021

Shiha Gamal, Soliman Reham, Elbasiony Mohamed, Darwish Noureldien H E, Mousa Shaker A

Abstract excerpt

The new anti-hepatitis C virus (HCV) molecules improve treatment regimens and outcomes, but there are drawbacks. New combinations should target the HCV infectious cycle and be effective against all HCV genotypes. We developed the novel formulation Catvira, composed of epigallocatechingallate (EGCG) + sofosbuvir + ribavirin. Here, we compared Catvira to sofosbuvir + ribavirin tablets in patients with CHC genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Catechin
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Pilot Projects

Share to Ribavirin

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 33633233
DOI: 10.1038/s41598-021-84066-3
PMCID: PMC7907074

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel combined single dose anti-hepatitis C therapy: a pilot study.PMID 33633233Read ↗

Regimens for the Hepatitis C Treatment-Naive Patient.Semantic proximity Read ↗

Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.Semantic proximity Read ↗

Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.Semantic proximity Read ↗

Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Semantic proximity Read ↗

New treatments for chronic hepatitis C virus infection.Semantic proximity Read ↗

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice.Semantic proximity Read ↗

Treatment of hepatitis C with new fixed dose combinations.Semantic proximity Read ↗

Exploratory study of oral combination antiviral therapy for hepatitis C.Semantic proximity Read ↗

A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.Semantic proximity Read ↗

Ravidasvir hydrochloride for genotype 1 hepatitis C treatment.Semantic proximity Read ↗

GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.